TSE:TRLTrilogy International Partners Stock Price, Forecast & News

C$1.43

+0.08 (+5.93 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

C$1.34

Now: C$1.43▼

C$1.44

50-Day Range

C$1.00

MA: C$1.23▼

C$1.45

52-Week Range

C$0.83

Now: C$1.43▼

C$3.45

Volume16,000 shs

Average Volume31,781 shs

Market CapitalizationC$84.20 million

P/E RatioN/A

Dividend Yield1.43%

BetaN/A

Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communication services in Bolivia and New Zealand. The company's communications services include local, international long distance, and roaming services for customers and international visitors roaming on their networks. It also provides fixed broadband communications services to business and residential customers. The company serves 15.9 million customers. Trilogy International Partners Inc. is headquartered in Bellevue, Washington.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Trilogy International Partners has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$2.50, Trilogy International Partners has a potential upside of 74.8% from its current price of C$1.43.
Amount of Analyst Coverage
Trilogy International Partners has only been the subject of 2 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Trilogy International Partners has received 209 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Trilogy International Partners has received 144 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Trilogy International Partners has received 59.21% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote “Outperform” if you believe TRL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Leadership
Trilogy International Partners is a leading dividend payer. It pays a dividend yield of 1.43%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Trilogy International Partners does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trilogy International Partners insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$540,000.00 in company stock and sold C$0.00 in company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Trilogy International Partners are expected to grow in the coming year, from C($0.40) to C$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trilogy International Partners is -19.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trilogy International Partners is -19.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Trilogy International Partners has a PEG Ratio of 21.78. PEG Ratios above 1 indicate that a company could be overvalued.

Overall Beat the Market Rank^™

2.36 out of 5 stars

Industry, Sector and Symbol

Stock Exchange TSE

Industry Drug Manufacturers - Major

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:TRL

Previous SymbolTSE:AQX.A

CUSIPN/A

CIKN/A

Webwww.trilogy-international.co...

Phone+1-425-4585900

Debt

Debt-to-Equity RatioN/A

Current Ratio0.87

Quick Ratio0.62

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E Growth21.78

Sales & Book Value

Annual SalesC$658.96 million

Price / Sales0.13

Cash FlowC$0.85 per share

Price / Cash Flow1.68

Book ValueC($1.10) per share

Price / Book-1.30

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees1,821

Outstanding Shares58,884,000

Market CapC$84.20 million

Next Earnings Date8/10/2020 (Estimated)

OptionableNot Optionable

Receive TRL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRL and its competitors with MarketBeat's FREE daily newsletter.

Trilogy International Partners (TSE:TRL) Frequently Asked Questions

How has Trilogy International Partners' stock been impacted by COVID-19 (Coronavirus)?

Trilogy International Partners' stock was trading at C$1.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRL stock has decreased by 24.7% and is now trading at C$1.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Trilogy International Partners?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trilogy International Partners.

When is Trilogy International Partners' next earnings date?

Trilogy International Partners is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Trilogy International Partners.

How were Trilogy International Partners' earnings last quarter?

Trilogy International Partners Inc (TSE:TRL) released its earnings results on Tuesday, March, 24th. The specialty pharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.44. The specialty pharmaceutical company had revenue of $219.23 million for the quarter. View Trilogy International Partners' earnings history.

What price target have analysts set for TRL?

2 Wall Street analysts have issued 1-year price targets for Trilogy International Partners' stock. Their forecasts range from C$1.70 to C$3.30. On average, they expect Trilogy International Partners' share price to reach C$2.50 in the next year. This suggests a possible upside of 74.8% from the stock's current price. View analysts' price targets for Trilogy International Partners.

Has Trilogy International Partners been receiving favorable news coverage?

Media stories about TRL stock have trended positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trilogy International Partners earned a daily sentiment score of 2.4 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutTrilogy International Partners.

Who are some of Trilogy International Partners' key competitors?

Some companies that are related to Trilogy International Partners include BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Recce Pharmaceuticals (RCE), Futura Medical (FUM), NanoViricides (NNVC), Vita Life Sciences (VLS), Pharmaxis (PXS), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Sareum (SAR), Patrys (PAB), Cathay International (CTI) and N4 Pharma (N4P). View all competitors.

What other stocks do shareholders of Trilogy International Partners own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Emera (EMA), Millicom International Cellular (MIICF), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONCYF), CSX (CSX), Check Cap (CHEK), Citizens Financial Group (CFG), Cboe Global Markets (CBOE) and CAE (CAE).

Who are Trilogy International Partners' key executives?

Trilogy International Partners' management team includes the following people:

Mr. John William Stanton, Chairman (Age 64)
Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)
Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)
Mr. Erik Mickels, Sr. VP & CFO
Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.

What is Trilogy International Partners' stock symbol?

Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."

How do I buy shares of Trilogy International Partners?

Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Trilogy International Partners' stock price today?

One share of TRL stock can currently be purchased for approximately C$1.43.

How big of a company is Trilogy International Partners?

Trilogy International Partners has a market capitalization of C$84.20 million and generates C$658.96 million in revenue each year. Trilogy International Partners employs 1,821 workers across the globe.

What is Trilogy International Partners' official website?

The official website for Trilogy International Partners is www.trilogy-international.co....

How can I contact Trilogy International Partners?

Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.

This page was last updated on 6/6/2020 by MarketBeat.com Staff